FDA Grants Rare Disease and Orphan Drug Status to Nobias for 22q11.2 Syndrome
January 3, 2025
Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, announced that the United States (U.S.) Food and Drug Administration (FDA) has granted